Do you have a question or suggestion?

Fill out the form and we will contact you as soon as possible. Thank you for your interest!



    Main Contacts  Pro EuroDILINet

    General enquiries:

    Dr Raul ANDRADE

    Prof Guruprasad AITHAL
    Vice Chair

    Dr Rossella MAGLI
    Science officer

    Ms Nathalie WARENGHIEN
    Administrative officer


    Prospective European Drug-Induced Liver Injury Network – CA17112

    There is a clear unmet need for a deeper understanding of idiosyncratic drug-induced liver injury (DILI), a multi-layered challenge that spans the life of the drug from pre-clinical development to clinical trials and post-marketing.

    The objectives of the PRO-EURO-DILI-NET Cost Action are to create a unique, co-operative, interdisciplinary European-based DILI network of stakeholders to co-ordinate efforts in DILI, to facilitate bi-directional exchange of discovered knowledge and generated hypotheses among different disciplines, and to promote clinically impactful knowledge discovery and its translation into clinical practice.

    This Action will:

    (a) harmonize efforts for in-depth DILI phenotyping and bio-sample repository and coordinate pre-funded database/repository studies to aggregate a large number of DILI cases in a standardized manner (WG1);

    (b) Establish a strategy for development, validation and performance of DILI novel biomarkers and explore multifactorial DILI risk modifiers in clinical data sets using novel approaches for future precision medicine (WG2);

    (c) Facilitate clinically impactful knowledge discovery by introducing biological variations and the complexity (i.e., multi-cellular/multi-organ systems) into toxicological experiments to assess hepatotoxicity to guide future drug safety testing (WG3).

    (d) Define criteria and establish endpoints to measure efficacy on novel interventions in DILI (WG4);

    (e) Draft policy recommendations about near-patient testing tools.

    The network will promote and coordinate a highly translational and innovative research program in Europe and beyond with the ultimate goal to pre-empt and prevent DILI, develop innovative therapeutic approaches that could improve clinical outcomes and enhance public awareness, while developing a forum for knowledge exchange and training of young European researches.

    Grant Periods (GP)

    GP1: 01 / 11 / 2018 → 30 / 04 / 2018

    GP2: 01 / 05 / 2019 → 30 / 04 / 2020

    GP3: 01 / 05 / 2020 → 30 / 04 / 2021

    GP4: 01 / 05 / 2021 → 15 / 10 / 2022

    For futher details link to COST CA-17112 in